NCT02110355View on ClinicalTrials.gov

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 19, 2014

Primary Completion Date

December 27, 2018

Study Completion Date

December 27, 2018

Conditions
Advanced MalignancyAdvanced Solid TumorsCancerOncologyOncology PatientsTumorsMelanoma
Interventions
DRUG

AMG 232

Given as an oral tablet in escalating doses

DRUG

Trametinib

Trametinib is an anti-cancer agent

DRUG

Dabrafenib

Dabrafenib is an anti-cancer agent

Trial Locations (7)

2060

Research Site, North Sydney

3000

Research Site, Melbourne

27599

Research Site, Chapel Hill

37232

Research Site, Nashville

80045

Research Site, Aurora

90095

Research Site, Los Angeles

02114

Research Site, Boston

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Kartos Therapeutics, Inc.

INDUSTRY

NCT02110355 - A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma | Biotech Hunter | Biotech Hunter